News for Healthier Living

RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.

May 7, 2026


May 16 2026

May 15 2026

May 14 2026

May 13 2026

May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026

May 6 2026

May 5 2026

May 4 2026